Transgene Will Present Oncolytic Virus Data in Phoenix
The company will debut preclinical results for its systemically delivered PoxSTG-EEV candidate on November 7, 2026.
Updated on Oct. 5, 2026 in Biotech
Transgene will present new preclinical data for PoxSTG-EEV, an enveloped oncolytic virus, at the SITC 2026 Annual Meeting in Phoenix. This research-stage immunotherapy is being evaluated for its ability to enable systemic delivery in cancer treatment.
Why it matters
The development represents a push toward systemic administration of oncolytic viruses, which typically struggle to reach tumor sites when delivered intravenously. Addressing these delivery barriers could improve the reach and efficacy of viral-based cancer immunotherapies.
The candidate PoxSTG-EEV is an enveloped oncolytic virus, a platform engineered to improve systemic delivery compared to traditional bare viral vectors. The technical performance of this delivery method will be detailed in abstract 1050 at the conference.
The players
Transgene
A biotechnology company based in Strasbourg, France, focused on developing virus-based immunotherapies for cancer treatment.
The details
Oncolytic viruses — modified viruses that selectively infect and kill tumor cells while stimulating an immune response — often face limitations with systemic delivery due to neutralization by the immune system. Transgene, a company based in Strasbourg, France, designed PoxSTG-EEV as an enveloped virion to potentially mask the virus and enhance its ability to reach target tumors. By adapting a chimeric PoxVirus, the research aims to overcome physiological barriers that currently restrict viral therapeutics to localized injections.
Timeline
November 3, 2026: The research abstract will be published on the SITC website.
November 4 - 8, 2026: The SITC 2026 Annual Meeting will take place in Phoenix.
November 7, 2026: Transgene will present the PoxSTG-EEV poster.
The Tech Race
The development of systemically deliverable oncolytic viruses remains a highly competitive objective within immuno-oncology. Transgene is positioning its PoxSTG-EEV platform against existing research programs that are currently evaluating non-enveloped or localized viral delivery methods.
This research is at an early preclinical stage and currently has no direct impact on clinical practice or available treatments. Practitioners and researchers can review the detailed technical findings following the release of the SITC abstract in early November.
The takeaway
The event highlights the industry’s continued technical focus on solving the systemic delivery problem for viral cancer treatments. Interested parties should watch for the release of abstract 1050 on November 3, 2026, to evaluate the efficacy claims of the PoxSTG-EEV platform.
Further reading
For broader trends in the industry, visit our Biotech section.
